Edison 
Mito Disease
Team
Clinical Trials
News
Technology
Contact
Clinical Trials
Leigh syndrome
A Phase 2B Randomized, Placebo-Controlled, Double-Blind Clinical Trial of EPI-743 in Children with Leigh Syndrome
Edison Pharmaceuticals is conducting a double-blind randomized placebo-controlled trial of EPI-743 for children with Leigh syndrome. The study is being conducted at four centers in the United States: Akron Children’s Hospital, Lucile Packard Children’s Hospital at Stanford, Seattle Children's Hospital, and Texas Children’s Hospital. For more information about trial enrollment please use the contact information below:
Study Sites
Akron Children’s Hospital
Akron, OH
Contact Hilary (Wolf) Tonni at htonni@chmca.org
Lucile Packard Children's Hospital, Stanford University Medical Center
Palo Alto, CA
Contact Katherine Connors at kconnors@stanford.edu
Seattle Children’s Hospital
Seattle, WA
Contact Laurie Guidry at laurie.guidry@seattlechildrens.org
Texas Children’s Hospital
Houston,TX
Contact Catherine Loffredo at catherine.loffredo@bcm.edu
Study Details
ClinicalTrials.gov
Friedreich's ataxia
A Phase 2B Double-Blind, Placebo-Controlled, Clinical Trial of EPI-743 in Friedreich’s Ataxia
Edison Pharmaceuticals is conducting a phase 2B placebo-controlled trial of EPI-743 in patients with Friedreich’s ataxia. The study is planned to be conducted at three centers in the United States that include: Children’s Hospital of Philadelphia, University of California, Los Angeles, and University of South Florida. For more information about trial enrollment please see the contact information below:
Study Sites
Children's Hospital of Philadelphia
Philadelphia, PA
Contact Lauren Sayer at seyerl@email.chop.edu
University of California, Los Angeles
Los Angeles, CA
Contact Maria Casado at mcasado@mednet.ucla.edu
University of South Florida
Tampa, FL
Contact Kelly Sullivan at kbarber@health.usf.edu
Study Details
ClinicalTrials.gov
© 2011 Edison Pharmaceuticals, Inc. All rights Reserved.